GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CohBar Inc (OTCPK:CWBR) » Definitions » EV-to-EBITDA

CohBar (CohBar) EV-to-EBITDA : 0.80 (As of May. 17, 2024)


View and export this data going back to 2015. Start your Free Trial

What is CohBar EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, CohBar's enterprise value is $-10.10 Mil. CohBar's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 was $-12.59 Mil. Therefore, CohBar's EV-to-EBITDA for today is 0.80.

The historical rank and industry rank for CohBar's EV-to-EBITDA or its related term are showing as below:

CWBR' s EV-to-EBITDA Range Over the Past 10 Years
Min: -92.31   Med: 0   Max: 84.63
Current: 0.8

During the past 10 years, the highest EV-to-EBITDA of CohBar was 84.63. The lowest was -92.31. And the median was 0.00.

CWBR's EV-to-EBITDA is ranked better than
72.21% of 457 companies
in the Biotechnology industry
Industry Median: 9.79 vs CWBR: 0.80

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-05-17), CohBar's stock price is $0.88. CohBar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 was $-4.360. Therefore, CohBar's PE Ratio for today is At Loss.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


CohBar EV-to-EBITDA Historical Data

The historical data trend for CohBar's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CohBar EV-to-EBITDA Chart

CohBar Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -7.51 -4.92 -4.03 -0.28 0.90

CohBar Quarterly Data
Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.30 0.90 0.90 0.81 0.33

Competitive Comparison of CohBar's EV-to-EBITDA

For the Biotechnology subindustry, CohBar's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CohBar's EV-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, CohBar's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where CohBar's EV-to-EBITDA falls into.



CohBar EV-to-EBITDA Calculation

CohBar's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=-10.102/-12.587
=0.80

CohBar's current Enterprise Value is $-10.10 Mil.
CohBar's EBITDA for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-12.59 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


CohBar  (OTCPK:CWBR) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

CohBar's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.88/-4.360
=At Loss

CohBar's share price for today is $0.88.
CohBar's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.360.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


CohBar EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of CohBar's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


CohBar (CohBar) Business Description

Traded in Other Exchanges
N/A
Address
1455 Adams Drive, Suite 2050, Menlo Park, CA, USA, 94025
CohBar Inc is a biotechnology company. It is engaged in the research and development of mitochondria-based therapeutics (MBTs) to treat various diseases associated with aging and metabolic dysfunction. The product portfolio of the company includes drugs such as CB4209 and CB4211, SHLP-6, SHLP-2, and new MBTs, these address a broad range of age-related diseases, including obesity, fatty liver disease, Type-2 diabetes, cancer, cardiovascular and neurodegenerative diseases. Geographically all the operations of the group functioned through the region of the United States.
Executives
Stephanie Tozzo director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Misha Petkevich director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joanne Yun director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Joseph J. Sarret director, officer: Chief Executive Officer C/O CODEXIS, INC., 200 PENOBSCOT DRIVE, REDWOOD CITY CA 94063
Carol Nast director C/O COHBAR, INC., 1455 ADAMS DRIVE, SUITE 2050, MENLO PARK CA 94025
Kenneth C Cundy officer: Chief Scientific Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jeffrey Francis Biunno officer: CFO, Treasurer and Secretary 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Steven B Engle officer: Chief Executive Officer C/O XOMA LTD., 2910 SEVENTH STREET, BERKELEY CA 94710
David Greenwood director 230 CONSTITUTION DRIVE, MENLO PARK CA 94025
Phyllis Gardner director 618 MIRADA AVENUE, STANFORD CA 94305
Philippe Calais director C/O MARINA BIOTECH, INC., 17870 CASTLETON STREET, SUITE 250, CITY OF INDUSTRY CA 91748
John Amatruda director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Simon Allen officer: Chief Executive Officer C/O AMBRX, INC., 10975 N. TORREY PINES RD., LA JOLLA CA 92037
Albion Fitzgerald director 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025
Jon Leland Stern director, officer: Chief Executive Officer 1455 ADAMS DRIVE, SUITE 2050, MENLO BUSINESS PARK, MENLO PARK CA 94025